Critical Contrast: BioCryst Pharmaceuticals (BCRX) & Vaxart (VXRT)

Share on StockTwits

BioCryst Pharmaceuticals (NASDAQ: BCRX) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

BioCryst Pharmaceuticals has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for BioCryst Pharmaceuticals and Vaxart, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 0 3 5 0 2.63
Vaxart 0 1 0 0 2.00

BioCryst Pharmaceuticals presently has a consensus price target of $9.58, indicating a potential upside of 31.28%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Vaxart.

Institutional & Insider Ownership

89.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.1% of Vaxart shares are owned by institutional investors. 5.2% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 44.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares BioCryst Pharmaceuticals and Vaxart’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -270.95% -96.05% -45.08%
Vaxart -317.57% -668.71% -43.85%

Earnings & Valuation

This table compares BioCryst Pharmaceuticals and Vaxart’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioCryst Pharmaceuticals $25.19 million 31.70 -$65.78 million ($0.78) -9.36
Vaxart $8.90 million 2.49 -$29.40 million N/A N/A

Vaxart has lower revenue, but higher earnings than BioCryst Pharmaceuticals.

Summary

BioCryst Pharmaceuticals beats Vaxart on 9 of the 12 factors compared between the two stocks.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

About Vaxart

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Set The Western Union Company  Price Target at $18.25
Brokerages Set The Western Union Company Price Target at $18.25
CaliphCoin Tops One Day Trading Volume of $0.00
CaliphCoin Tops One Day Trading Volume of $0.00
Analysts Anticipate Acadia Healthcare Company Inc  Will Post Earnings of $0.65 Per Share
Analysts Anticipate Acadia Healthcare Company Inc Will Post Earnings of $0.65 Per Share
Somewhat Negative News Coverage Somewhat Unlikely to Impact BIO-key International  Stock Price
Somewhat Negative News Coverage Somewhat Unlikely to Impact BIO-key International Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Burcon Nutrascience  Share Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Burcon Nutrascience Share Price
Zacks: Analysts Anticipate Pool Co.  to Announce $1.57 EPS
Zacks: Analysts Anticipate Pool Co. to Announce $1.57 EPS


Leave a Reply

© 2006-2018 Ticker Report. Google+.